Lexaria Bioscience : Departure of Directors or Certain Officers (Form 8-K)

Departure of Directors or Certain Officers

Brian Quigley, an independent director of Lexaria Bioscience Corp. (the 'Company'), advised the Board of Directors of the Company (the 'Board') that he would not be standing for re-election at the Company's next annual shareholder meeting. Accordingly, at the annual meeting of shareholders, held on June 28, 2021 (the 'Meeting'), Mr. Quigley was not presented as a director nominee and was not re-elected to the Board.

Submission of Matters to a Vote of Security Holders

On June 28, 2021 at 1:00 p.m. (Pacific Time), the Company held the Meeting. There were 2,735,413 shares of the Company represented in person or by proxy at the meeting, constituting 53.6% of the Company's issued share capital as at May 3, 2021, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:

Matter Being Voted On	For	Against	Abstain	Broker Non-Vote	Percent Approved By1
To Elect Chris Bunka as a director	1,389,144	30,938	7,703	1,307,628	97.2%
To Elect John Docherty as a director	1,175,573	245,394	6,818	1,307,628	82.3%
To Elect Nicholas Baxter as a director	1,171,626	249,276	6,883	1,307,628	82.1%
To Elect Ted McKechnie as a director	1,394,635	26,310	6,840	1,307,628	97.7%
To Elect Albert Reese Jr. as a director	1,393,765	27,167	6,853	1,307,628	97.6%
To Appoint Davidson & Company LLP as Auditors	2,713,114	17,792	4,504	0	99.2%
To Approve an amendment to the Company's Equity Incentive Plan for the issuance of an additional 249,143 common shares	975,355	442,816	9,614	1,307,628	68.3%
To Ratify the lawful actions of the directors for the past year	1,225,531	55,303	146,951	1,307,628	85.8%

¹ Percentage is calculated based on abstained votes being counted as a vote against the resolution.

All of the proposals are described in detail in the Company's proxy statement filed with the Securities and Exchange Commission on May 14, 2021.

2